Contraceptive Pills Market to Reach USD 20.55 billion by 2026; Increasing Uptake of Combined Contraceptive Pills to Foster Greater Sales Opportunities

The global contraceptive pills market size is set to hit USD 20.55 billion by 2026 owing to the rising need to bring down the rate of unintended pregnancies. According to a new Fortune Business Insights report, titled “Contraceptive Pills Market Size, Share & Industry Analysis, By Type (Combination Pills and Progestin-only Pills), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGO, and Others) and Regional Forecast, 2019-2026”, the market value stood at USD 13.11 billion in 2018. The market is expected to exhibit a CAGR of 5.8% during the forecast period, 2019-2026.

Growing Awareness about the Different Aspects of Sex to Boost the Market Prospects

One of the most prominent contraceptive pills market trends is the steadily spreading awareness about sex and sexual activity around the world. This has pushed up the adoption rate of birth-control pills, especially the over-the-counter (OTC) contraceptive pills. For example, research conducted by the United Nations found that over 20% of women in the reproductive age category in 27 countries used contraceptive pills. Moreover, rising incidence of teenage pregnancy is fueling the oral contraceptives market. The Centers for Disease Control and Prevention (CDC) states that 64.9% of the 72.2 million women used birth-control pills between 2015 and 2017. Of these 12.6% preferred oral contraceptives. Thus, the birth-control pills market growth will get an upward thrust in the process.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/contraceptive-pills-market-101802

Market Segmentation:

• By Type: On the basis of type, the market is divided into combined contraceptives and progestin-only contraceptives. Accounting for the largest share in 2018, the combined contraceptives segment is anticipated to lead till 2026. These pills can control monthly menstrual cycles and manage pre-menstrual syndrome more efficiently as they contain both progesterone and estrogen hormones, thereby aiding this segment’s growth. The other segment is also projected to rise at a healthy pace in the forecast period.


• By Distribution Channel: Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, clinics, online channels, public channel & NGOs, and others. Amongst these, the retail pharmacy segment is expected to lead as the segment held the largest market share in 2018. The dominance of this segment is attributable to the increasing sale of over-the-counter (OTC) birth-control pills and growing awareness regarding contraceptives. On the other hand, the online channel segment will exhibit the highest CAGR on account of development of e-pharmacy platforms. The rest of the segments will also grow considerably during the forecast period.


• By Region: Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Having generated USD 4.09 billion in revenue in 2018, North America is poised to dominate the contraceptive pills market share. This will be owing to increasingly favorable reimbursement policies for oral contraceptives and rising adoption of short-acting reversible contraception in the U.S. Increasing prevalence of teenage pregnancy will also fuel the contraceptive pills market growth during the forecast period.

Emergence of Smaller Companies to Inject Fresh Energy into the Market

The contraceptive pills market analysis shows that the market is set to experience a period of intense competition owing to the growth of smaller players. Even though big companies command majority market share, many of them have encountered capacity snags. Few of them had to call back some of their most popular products. For instance, Allergan had to recall Taytulla, its flagship birth-control capsules, due to packaging errors.

Some of the key players covered in the contraceptive pills market report include:

• Piramal Enterprises


• HLL Lifecare Limited


• Bayer AG


• Teva Pharmaceutical Industries


• Pfizer, Inc.


• Mylan N.V.


• Janssen Pharmaceutical Company


• Allergan, plc


• Merck & Co., Inc.

Key Industry Developments:

• April 2018: Mylan N.V. commercially introduced generic version of Bayer's Yaz, Ethinyl Estradiol and Drospirenone tablets, in the U.S. market. The tablets are engineered to treat acne vulgaris and prevent pregnancy in women.


• December 2017: US FDA green lit Tydemy tablets developed by Lupin Pharmaceuticals. These are intended to increase foliate levels in women who use oral contraceptives.

The Global Contraceptive Pills Market is Segmented in the Following Manner: